Zoetis will continue funding free Human–Animal Bond Certification for U.S. veterinary students in 2026 and has expanded the scholarship to include veterinary technician students for the first time.
Zoetis will acquire Neogen’s animal genomics business for $160 million, strengthening its Precision Animal Health capabilities across livestock and companion animals worldwide.
Zoetis will participate in the Bank of America Securities 2026 Animal Health Summit on February 26, with CFO Wetteny Joseph representing the company.
Zoetis has launched the first commercial genetic predictions for bovine respiratory disease, giving beef producers new tools to select cattle with stronger genetic potential for health, survival, and profitability.
Zoetis’ Board of Directors has declared a quarterly dividend of $0.53 per share, payable June 2, 2026, to shareholders of record as of April 20, 2026.
A $250,000 grant from the Zoetis Foundation will enable the North American Veterinary Community to expand its Believe & Belong in Veterinary Medicine® program, increasing access to education, mentorship, and career exposure for aspiring veterinary students.
Zoetis has announced the planned retirement of Dr. Rob Polzer, Executive Vice President and President of R&D, at the end of 2025. Dr. Kevin Esch will succeed him as President of Research & Development, effective January 1, 2026.
Zoetis reported third quarter 2025 revenue of $2.4 billion, up 1% year-over-year, with 4% organic operational growth and a 9% increase in adjusted net income. The company revised full-year guidance based on macro trends and disciplined cost management.
Zoetis’ newly approved Portela® (relfovetmab) becomes the first feline osteoarthritis treatment offering three months of pain relief from a single injection, with EU launch expected in 2026.
Zoetis’ Lenivia® (izenivetmab) receives Health Canada approval and a positive opinion from the European Medicines Agency, paving the way for the world’s first three-month monoclonal antibody therapy for canine osteoarthritis pain.